These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 12692224)

  • 1. Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells.
    Guebre-Xabier M; Hammond SA; Epperson DE; Yu J; Ellingsworth L; Glenn GM
    J Virol; 2003 May; 77(9):5218-25. PubMed ID: 12692224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice.
    Guebre-Xabier M; Hammond SA; Ellingsworth LR; Glenn GM
    J Virol; 2004 Jul; 78(14):7610-8. PubMed ID: 15220436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
    Glenn GM; Thomas DN; Poffenberger KL; Flyer DC; Ellingsworth LR; Andersen BH; Frech SA
    Vaccine; 2009 Dec; 27 Suppl 6():G60-6. PubMed ID: 20006142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine.
    Katz JM; Lu X; Young SA; Galphin JC
    J Infect Dis; 1997 Feb; 175(2):352-63. PubMed ID: 9203656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch.
    Frech SA; Kenney RT; Spyr CA; Lazar H; Viret JF; Herzog C; Glück R; Glenn GM
    Vaccine; 2005 Jan; 23(7):946-50. PubMed ID: 15603897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization.
    Barackman JD; Ott G; Pine S; O'Hagan DT
    Clin Diagn Lab Immunol; 2001 May; 8(3):652-7. PubMed ID: 11329476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.
    Stephenson I; Zambon MC; Rudin A; Colegate A; Podda A; Bugarini R; Del Giudice G; Minutello A; Bonnington S; Holmgren J; Mills KH; Nicholson KG
    J Virol; 2006 May; 80(10):4962-70. PubMed ID: 16641287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
    Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
    J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin.
    Hashigucci K; Ogawa H; Ishidate T; Yamashita R; Kamiya H; Watanabe K; Hattori N; Sato T; Suzuki Y; Nagamine T; Aizawa C; Tamura S; Kurata T; Oya A
    Vaccine; 1996 Feb; 14(2):113-9. PubMed ID: 8852406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.
    Tumpey TM; Renshaw M; Clements JD; Katz JM
    J Virol; 2001 Jun; 75(11):5141-50. PubMed ID: 11333895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge.
    Beignon AS; Briand JP; Muller S; Partidos CD
    Immunology; 2001 Mar; 102(3):344-51. PubMed ID: 11298834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine.
    Tamura S; Asanuma H; Tomita T; Komase K; Kawahara K; Danbara H; Hattori N; Watanabe K; Suzuki Y; Nagamine T
    Vaccine; 1994 Sep; 12(12):1083-9. PubMed ID: 7998417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine.
    Lu X; Clements JD; Katz JM
    Vaccine; 2002 Jan; 20(7-8):1019-29. PubMed ID: 11803061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen.
    Verweij WR; de Haan L; Holtrop M; Agsteribbe E; Brands R; van Scharrenburg GJ; Wilschut J
    Vaccine; 1998 Dec; 16(20):2069-76. PubMed ID: 9796066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization.
    Barackman JD; Ott G; O'Hagan DT
    Infect Immun; 1999 Aug; 67(8):4276-9. PubMed ID: 10417205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine.
    Hagiwar Y; Tsuji T; Iwasaki T; Kadowaki S; Asanuma H; Chen Z; Komase K; Suzuki Y; Aizawa C; Kurata T; Tamura S
    Vaccine; 2001 Feb; 19(15-16):2071-9. PubMed ID: 11228379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines.
    Davtyan H; Ghochikyan A; Hovakimyan A; Petrushina I; Yu J; Flyer D; Madsen PJ; Pedersen LO; Cribbs DH; Agadjanyan MG
    J Neuroimmunol; 2014 Mar; 268(1-2):50-7. PubMed ID: 24507620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TLR2-dependent modulation of dendritic cells by LT-IIa-B5, a novel mucosal adjuvant derived from a type II heat-labile enterotoxin.
    Lee CH; Masso-Welch P; Hajishengallis G; Connell TD
    J Leukoc Biol; 2011 Nov; 90(5):911-21. PubMed ID: 21791597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intradermal administration of the Type II heat-labile enterotoxins LT-IIb and LT-IIc of enterotoxigenic Escherichia coli enhances humoral and CD8+ T cell immunity to a co-administered antigen.
    Hu JC; Mathias-Santos C; Greene CJ; King-Lyons ND; Rodrigues JF; Hajishengallis G; Ferreira LC; Connell TD
    PLoS One; 2014; 9(12):e113978. PubMed ID: 25536061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate imprinting by the modified heat-labile toxin of Escherichia coli (LTK63) provides generic protection against lung infectious disease.
    Williams AE; Edwards L; Humphreys IR; Snelgrove R; Rae A; Rappuoli R; Hussell T
    J Immunol; 2004 Dec; 173(12):7435-43. PubMed ID: 15585869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.